The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPARα.

Autor: Clavreul L; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Bernard L; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Cotte AK; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Hennuyer N; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Bourouh C; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Devos C; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Helleboid A; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Haas JT; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Verrijken A; Laboratory of Experimental Medicine and Paediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, 1 B-2610 Antwerp, Belgium; Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, 1 B-2610 Antwerp, Belgium., Gheeraert C; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Derudas B; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Guille L; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Chevalier J; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Eeckhoute J; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Vallez E; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Dorchies E; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Van Gaal L; Laboratory of Experimental Medicine and Paediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, 1 B-2610 Antwerp, Belgium; Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, 1 B-2610 Antwerp, Belgium., Lassailly G; Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, 1 place de Verdun, 59000 Lille, France., Francque S; Laboratory of Experimental Medicine and Paediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, 1 B-2610 Antwerp, Belgium; Department of Gastroenterology and Hepatology, Antwerp University Hospital, 1 B-2610 Antwerp, Belgium; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Germany., Staels B; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France., Paumelle R; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011, EGID, Boulevard du Professeur Jules Leclercq, 59045 Lille, France. Electronic address: rejane.lestrelin@univ-lille.fr.

Publikováno v: Metabolism: clinical and experimental [Metabolism] 2024 Feb; Vol. 151, pp. 155720. Date of Electronic Publication: 2023 Nov 03.

Chrysin-Induced Regression of Angiogenesis via an Induction of DNA Damage Response and Oxidative Stress in In Vitro and In Vivo Models of Melanoma.

Autor: Sassi A; UFR Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.; INSERM Research Center U1231-Cancer and Adaptive Immune Response Team, Bioactive Molecules and Health Research Group, 21000 Dijon, France.; Research Unit Bioactive Natural Products and Biotechnology UR17ES49, Faculty of Dental Medicine of Monastir, University of Monastir, Avicenne Street, Monastir 5000, Tunisia., Fredon M; UFR Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.; INSERM Research Center U1231-Cancer and Adaptive Immune Response Team, Bioactive Molecules and Health Research Group, 21000 Dijon, France., Cotte AK; UFR Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.; INSERM Research Center U1231-Cancer and Adaptive Immune Response Team, Bioactive Molecules and Health Research Group, 21000 Dijon, France., Fuselier C; Faculté des Sciences Exactes et Naturelles, UMR CNRS 7369 MEDyC, Université de Reims Champagne Ardenne, 51687 Reims, France., Schneider C; Faculté des Sciences Exactes et Naturelles, UMR CNRS 7369 MEDyC, Université de Reims Champagne Ardenne, 51687 Reims, France., Martiny L; Faculté des Sciences Exactes et Naturelles, UMR CNRS 7369 MEDyC, Université de Reims Champagne Ardenne, 51687 Reims, France., Monchaud D; UFR Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.; Institut de Chimie Moléculaire (ICMUB), CNRS UMR6302, UBFC, 21078 Dijon, France., Chekir-Ghedira L; Research Unit Bioactive Natural Products and Biotechnology UR17ES49, Faculty of Dental Medicine of Monastir, University of Monastir, Avicenne Street, Monastir 5000, Tunisia., Aires V; UFR Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.; INSERM Research Center U1231-Cancer and Adaptive Immune Response Team, Bioactive Molecules and Health Research Group, 21000 Dijon, France., Delmas D; UFR Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.; INSERM Research Center U1231-Cancer and Adaptive Immune Response Team, Bioactive Molecules and Health Research Group, 21000 Dijon, France.; Centre de Lutte Contre le Cancer Georges François Leclerc Center, 21000 Dijon, France.

Publikováno v: Cells [Cells] 2023 Jun 06; Vol. 12 (12). Date of Electronic Publication: 2023 Jun 06.

Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis.

Autor: Bobowski-Gerard M; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Boulet C; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Zummo FP; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Dubois-Chevalier J; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Gheeraert C; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Bou Saleh M; Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France., Strub JM; Laboratoire de Spectrométrie de Masse BioOrganique, CNRS UMR7178, Univ Strasbourg, IPHC, Infrastructure Nationale de Protéomique ProFI - FR2048, 67087, Strasbourg, France., Farce A; Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France., Ploton M; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Guille L; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Vandel J; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Bongiovanni A; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000, Lille, France., Very N; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Woitrain E; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Deprince A; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Lalloyer F; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Bauge E; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Ferri L; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Ntandja-Wandji LC; Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France., Cotte AK; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Grangette C; U1019-UMR 9017-CIIL-Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHU Lille, F-59000, Lille, France., Vallez E; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Cianférani S; Laboratoire de Spectrométrie de Masse BioOrganique, CNRS UMR7178, Univ Strasbourg, IPHC, Infrastructure Nationale de Protéomique ProFI - FR2048, 67087, Strasbourg, France., Raverdy V; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190-EGID, Translational Research in Diabetes, Lille, France., Caiazzo R; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190-EGID, Translational Research in Diabetes, Lille, France., Gnemmi V; Service d'anatomopathologie, Centre Hospitalier Universitaire de Lille, Université de Lille, INSERM UMR-S 1172, Lille, France., Leteurtre E; Service d'anatomopathologie, Centre Hospitalier Universitaire de Lille, Université de Lille, INSERM UMR-S 1172, Lille, France., Pourcet B; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Paumelle R; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Ravnskjaer K; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, 5230, Denmark.; Center for Functional Genomics and Tissue Plasticity (ATLAS), University of Southern Denmark, Odense, 5230, Denmark., Lassailly G; Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France., Haas JT; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Mathurin P; Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France., Pattou F; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190-EGID, Translational Research in Diabetes, Lille, France., Dubuquoy L; Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France., Staels B; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Lefebvre P; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France., Eeckhoute J; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France. jerome.eeckhoute@inserm.fr.

Publikováno v: Nature communications [Nat Commun] 2022 Sep 10; Vol. 13 (1), pp. 5324. Date of Electronic Publication: 2022 Sep 10.

Phospholipid profiles and hepatocellular carcinoma risk and prognosis in cirrhotic patients.

Autor: Cotte AK; University of Bourgogne, Franche-Comté, Dijon, France.; INSERM U1231 'Lipids, Nutrition, Cancer', Research Team Cancer and Adaptive Immune Response (CADIR), Dijon, France., Cottet V; University of Bourgogne, Franche-Comté, Dijon, France.; INSERM U1231 'Lipids, Nutrition, Cancer', Research Team Epidemiology and Clinical Research in Digestive Oncology (EPICAD), Dijon, France.; Inserm, Clinical Investigation Center, Dijon, France., Aires V; University of Bourgogne, Franche-Comté, Dijon, France.; INSERM U1231 'Lipids, Nutrition, Cancer', Research Team Cancer and Adaptive Immune Response (CADIR), Dijon, France., Mouillot T; Department of Hepatogastroenterology, University Hospital, Dijon, France., Rizk M; University of Bourgogne, Franche-Comté, Dijon, France.; INSERM U1231 'Lipids, Nutrition, Cancer', Research Team Epidemiology and Clinical Research in Digestive Oncology (EPICAD), Dijon, France., Vinault S; University of Bourgogne, Franche-Comté, Dijon, France.; Inserm, Clinical Investigation Center, Dijon, France., Binquet C; University of Bourgogne, Franche-Comté, Dijon, France.; INSERM U1231 'Lipids, Nutrition, Cancer', Research Team Epidemiology and Clinical Research in Digestive Oncology (EPICAD), Dijon, France.; Department of Hepatogastroenterology, University Hospital, Dijon, France., de Barros JP; University of Bourgogne, Franche-Comté, Dijon, France.; Lipidomic Platform, Dijon, France., Hillon P; University of Bourgogne, Franche-Comté, Dijon, France.; INSERM U1231 'Lipids, Nutrition, Cancer', Research Team Epidemiology and Clinical Research in Digestive Oncology (EPICAD), Dijon, France.; Department of Hepatogastroenterology, University Hospital, Dijon, France., Delmas D; University of Bourgogne, Franche-Comté, Dijon, France.; INSERM U1231 'Lipids, Nutrition, Cancer', Research Team Cancer and Adaptive Immune Response (CADIR), Dijon, France.

Publikováno v: Oncotarget [Oncotarget] 2019 Mar 15; Vol. 10 (22), pp. 2161-2172. Date of Electronic Publication: 2019 Mar 15 (Print Publication: 2019).

Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.

Autor: Cotte AK; University of Bourgogne-Franche Comté, F-21000, Dijon, France. alexiakm.cotte@gmail.com.; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France. alexiakm.cotte@gmail.com.; Research Team CADIR, Cancer and Adaptative Immune Response, F-21000, Dijon, France. alexiakm.cotte@gmail.com., Aires V; University of Bourgogne-Franche Comté, F-21000, Dijon, France.; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France.; Research Team CADIR, Cancer and Adaptative Immune Response, F-21000, Dijon, France., Fredon M; University of Bourgogne-Franche Comté, F-21000, Dijon, France.; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France.; Research Team CADIR, Cancer and Adaptative Immune Response, F-21000, Dijon, France., Limagne E; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France.; Research Team CADIR, Cancer and Adaptative Immune Response, F-21000, Dijon, France.; Transfer platform in cancer biology, Department of biology and tumour pathology, Georges François Leclerc Centre, F-21000, Dijon, France., Derangère V; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France.; Research Team CADIR, Cancer and Adaptative Immune Response, F-21000, Dijon, France.; Transfer platform in cancer biology, Department of biology and tumour pathology, Georges François Leclerc Centre, F-21000, Dijon, France., Thibaudin M; University of Bourgogne-Franche Comté, F-21000, Dijon, France.; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France.; Research Team CADIR, Cancer and Adaptative Immune Response, F-21000, Dijon, France., Humblin E; University of Bourgogne-Franche Comté, F-21000, Dijon, France.; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France.; Research Team CADIR, Cancer and Adaptative Immune Response, F-21000, Dijon, France., Scagliarini A; University of Bourgogne-Franche Comté, F-21000, Dijon, France.; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France.; Research Team CADIR, Cancer and Adaptative Immune Response, F-21000, Dijon, France., de Barros JP; University of Bourgogne-Franche Comté, F-21000, Dijon, France.; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France.; Lipidomic Platform, F-21000, Dijon, France., Hillon P; University of Bourgogne-Franche Comté, F-21000, Dijon, France.; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France.; Department of Hepatogastroenterology, University Hospital, F-21000, Dijon, France., Ghiringhelli F; University of Bourgogne-Franche Comté, F-21000, Dijon, France.; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France.; Research Team CADIR, Cancer and Adaptative Immune Response, F-21000, Dijon, France.; Department of medical Oncology, Georges François Leclerc Centre, F-21000, Dijon, France., Delmas D; University of Bourgogne-Franche Comté, F-21000, Dijon, France. dominique.delmas@u-bourgogne.fr.; INSERM U1231, Lipids, Nutrition, Cancer, F-21000, Dijon, France. dominique.delmas@u-bourgogne.fr.; Research Team CADIR, Cancer and Adaptative Immune Response, F-21000, Dijon, France. dominique.delmas@u-bourgogne.fr.

Publikováno v: Nature communications [Nat Commun] 2018 Jan 22; Vol. 9 (1), pp. 322. Date of Electronic Publication: 2018 Jan 22.